Blue Capital Inc. Takes $688,000 Position in Bristol Myers Squibb Company $BMY

Blue Capital Inc. bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, HoldingsChannel reports. The firm bought 12,753 shares of the biopharmaceutical company’s stock, valued at approximately $688,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank increased its stake in Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares during the period. Marshall Wace LLP purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth $221,000. Finally, Nebula Research & Development LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter worth $405,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a quarterly dividend of $0.63 per share, reinforcing its income appeal with an annualized yield of about 4.6%. Bristol Myers Squibb Announces Dividend
• Positive Sentiment: The company reported positive Phase III SUCCESSOR-2 multiple myeloma data and additional encouraging pipeline results at the EHA 2026 conference, which could strengthen optimism around future oncology growth. Bristol Myers Squibb (BMY) Unveils Myeloma Trial Win And New Gulf Leadership
• Positive Sentiment: Independent coverage highlighted potential undervaluation in BMY, citing pipeline progress and margin improvement as reasons the stock may have upside from current levels. Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes
• Neutral Sentiment: Bristol Myers Squibb said it will report second-quarter 2026 results on July 30, keeping investors focused on the next earnings update. Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
• Neutral Sentiment: The company also appointed a new general manager for Saudi Arabia and Gulf countries, a strategic regional leadership move with limited near-term stock impact. Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
• Negative Sentiment: Recent trading has been soft, with shares declining over the past month and quarter, and analysts still broadly rating the stock as a hold. Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Insider Buying and Selling

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Cantor Fitzgerald raised their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. Finally, HSBC lifted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $54.10 on Friday. The firm has a fifty day moving average of $57.44 and a two-hundred day moving average of $57.11. The firm has a market cap of $110.48 billion, a P/E ratio of 15.20, a P/E/G ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the business posted $1.80 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.7%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.